ASHLEY FITZHUGH: Open Payments
NPI 1356980817 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,230 in 49 payments from 11 companies in 2025. Trend: 2023 $793 · 2024 $1,140 · 2025 $1,230
Food & beverage: $1,230
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 11 | $308 |
| Merck Sharp & Dohme LLC | 8 | $207 |
| Eisai Inc. | 4 | $183 |
| Genmab U.S., Inc. | 5 | $124 |
| ABBVIE INC. | 5 | $93 |
| AstraZeneca Pharmaceuticals LP | 5 | $86 |
| Caris MPI, Inc. | 3 | $55 |
| VERTEX PHARMACEUTICALS INCORPORATED | 3 | $54 |
| Myriad Genetic Laboratories, Inc. | 2 | $54 |
| Astellas Pharma US Inc | 2 | $42 |
Products named: JEMPERLI, Lenvima, KEYTRUDA, LYNPARZA, ELAHERE, Tivdak, MI CANCER SEEK, JOURNAVX.
Industry payments across MS — which companies pay providers there.
